BR112012015659A2 - compostos de carboxamida e seu uso como inibidores de calpaína - Google Patents

compostos de carboxamida e seu uso como inibidores de calpaína

Info

Publication number
BR112012015659A2
BR112012015659A2 BR112012015659A BR112012015659A BR112012015659A2 BR 112012015659 A2 BR112012015659 A2 BR 112012015659A2 BR 112012015659 A BR112012015659 A BR 112012015659A BR 112012015659 A BR112012015659 A BR 112012015659A BR 112012015659 A2 BR112012015659 A2 BR 112012015659A2
Authority
BR
Brazil
Prior art keywords
alkyl
carboxamide compounds
compounds
calpain inhibitors
aryl
Prior art date
Application number
BR112012015659A
Other languages
English (en)
Inventor
Achim Möller
Andreas Kling
Gisela Backfisch
Helmut Mack
Katja Jantos
Marjoleen Nijsen
Wilfried Hornberger
Yanbin Lao
Original Assignee
Abbott Lab
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab, Abbott Gmbh & Co Kg filed Critical Abbott Lab
Publication of BR112012015659A2 publication Critical patent/BR112012015659A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

compostos de carboxamida e seu uso como inibidores de calpaína. a presente invenção refere-se a novos compostos de carboxamida e seu uso para a fabricação de um medicamento. os compostos de carboxamida são inibidores de calpaína (proteases de cisteína dependentes de cálcio). a invenção, portanto, também se refere á utilização destes compostos de carboxamida para o tratamento de um distúrbio associado a uma elevada atividade de calpaína. os compostos de carboxamida são compostoes da fórmula geral i em que r^ 1^, r^ 2^, r^ 3^, r^ 4^, r^ 5^, m e n tem os significados mencionados nas reivindicações e a descrição, os tautômeros do mesmos, os hidratos dos mesmos e os sais farmaceuticamente aceitáveis dos mesmos. destes compostos, são preferidos aqueles em que r^ 1^ é fenil-c~ 1~-c~ 2~-alquila ou hetaril-c~ 1~-c~ 2~alquila opcionalmente substituído, r^ 2^ é arila opcionalmente substituído, hetarila, aril-c~ 1~-c~ 6~-aqluila, aril-c~ 2~-c~ 6~-alquenila ou heraril-c~ 1~-c~ 4~-alquila, r^ 3^ é c~ 1~-c~ 3~-alquila, c~ 1~-c~ 3~-alquila, r^ 4^ e r^ 5^, independemente um do outro, são halogênio, cf~ 3~, chf~ 2~,ch~ 2~f, c~ 1~-c~ 2~-alquila ou c~ 1~-c~ 2-alcóxi, e m e n, independentemente um do outro, são 0 ou 1.
BR112012015659A 2009-12-22 2010-12-21 compostos de carboxamida e seu uso como inibidores de calpaína BR112012015659A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28893509P 2009-12-22 2009-12-22
US41041410P 2010-11-05 2010-11-05
PCT/EP2010/070418 WO2011076811A1 (en) 2009-12-22 2010-12-21 Carboxamide compounds and their use as calpain inhibitors

Publications (1)

Publication Number Publication Date
BR112012015659A2 true BR112012015659A2 (pt) 2016-05-24

Family

ID=43501481

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012015659A BR112012015659A2 (pt) 2009-12-22 2010-12-21 compostos de carboxamida e seu uso como inibidores de calpaína

Country Status (19)

Country Link
US (2) US9051304B2 (pt)
EP (1) EP2516393B1 (pt)
KR (1) KR20120102132A (pt)
CN (1) CN102933548B (pt)
AR (1) AR079668A1 (pt)
AU (1) AU2010334915B2 (pt)
BR (1) BR112012015659A2 (pt)
CA (1) CA2783704A1 (pt)
ES (1) ES2525149T3 (pt)
HK (1) HK1176066A1 (pt)
IL (1) IL220586A (pt)
MX (1) MX2012007323A (pt)
NZ (1) NZ600342A (pt)
RU (1) RU2567392C2 (pt)
SG (1) SG181915A1 (pt)
TW (1) TW201138771A (pt)
UY (1) UY33150A (pt)
WO (1) WO2011076811A1 (pt)
ZA (1) ZA201204496B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103501784A (zh) * 2010-12-09 2014-01-08 Abbvie德国有限责任两合公司 甲酰胺化合物及它们作为钙蛋白酶抑制剂v的用途
CN104364247A (zh) 2012-04-03 2015-02-18 艾伯维德国有限责任两合公司 甲酰胺化合物及它们作为钙蛋白酶抑制剂v的用途
US9604961B2 (en) 2012-12-06 2017-03-28 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
JP6962564B2 (ja) 2015-10-08 2021-11-05 株式会社Pal 筋肉損傷や筋肉疲労の抑制剤
US10590084B2 (en) 2016-03-09 2020-03-17 Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
WO2018009417A1 (en) 2016-07-05 2018-01-11 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
US10934261B2 (en) 2016-09-28 2021-03-02 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
AU2019242387A1 (en) * 2018-03-28 2020-11-19 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826835A (en) 1985-10-23 1989-05-02 Rorer Pharmaceutical Corporation Pyridyl-pyridazinone and pyridyl-pyrazolinone compounds and their use in the treatment of congestive heart failure
US4743608A (en) 1986-07-15 1988-05-10 Rorer Pharmaceutical Corporation Pyridone-pyridyl-imidazolyl and triazolyl compounds and their use as cardiotonic agents
DK0708085T3 (da) * 1994-10-19 2002-11-11 Novartis Ag Antivirale ethere af aspartatproteasesubstrat-isostere
DE19642591A1 (de) 1996-10-15 1998-04-16 Basf Ag Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung
DE19650975A1 (de) 1996-12-09 1998-06-10 Basf Ag Neue heterocyclisch substituierte Benzamide und deren Anwendung
AU721620B2 (en) 1996-12-11 2000-07-13 Basf Aktiengesellschaft Novel ketobenzamides and their use
US6083944A (en) 1997-10-07 2000-07-04 Cephalon, Inc. Quinoline-containing α-ketoamide cysteine and serine protease inhibitors
DE19817459A1 (de) 1998-04-20 1999-10-21 Basf Ag Neue heterozyklische substituierte Amide, Herstellung und Anwendung
BR9909819A (pt) 1998-04-20 2000-12-19 Basf Ag Amida, uso de amidas, e, preparação farmacêutica para uso oral, parenteral ou intraperitoneal
SK14512000A3 (sk) 1998-04-20 2001-04-09 Basf Aktiengesellschaft Substituované amidy, ich príprava a použitie
DE19818614A1 (de) 1998-04-20 1999-10-21 Basf Ag Neue substituierte Amide, deren Herstellung und Anwendung
WO1999054305A1 (de) 1998-04-20 1999-10-28 Basf Aktiengesellschaft Heterocyclisch substituierte amide als calpainhemmer
EP1080074B1 (de) 1998-05-25 2006-11-08 Abbott GmbH & Co. KG Heterocyclische substituierte Amide, deren Herstellung und Verwendung
DE10114762A1 (de) 2001-03-26 2002-10-02 Knoll Gmbh Verwendung von Cysteinprotease-Inhibitoren
CA2477657C (en) * 2002-03-05 2011-04-26 Merck Frosst Canada & Co./Merck Frosst Canada & Cie Cathepsin cysteine protease inhibitors
JP2009505966A (ja) 2005-08-02 2009-02-12 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼのインヒビター
RU2485114C2 (ru) 2006-12-29 2013-06-20 Эбботт Гмбх Унд Ко.Кг Карбоксамидные соединения и их применение в качестве ингибиторов кальпаинов
US8435984B2 (en) 2007-02-26 2013-05-07 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of HCV replication
TWI519530B (zh) 2009-02-20 2016-02-01 艾伯維德國有限及兩合公司 羰醯胺化合物及其作為鈣蛋白酶（ｃａｌｐａｉｎ）抑制劑之用途
US8236798B2 (en) 2009-05-07 2012-08-07 Abbott Gmbh & Co. Kg Carboxamide compounds and their use as calpain inhibitors

Also Published As

Publication number Publication date
UY33150A (es) 2011-06-30
JP2013515039A (ja) 2013-05-02
ES2525149T3 (es) 2014-12-18
AU2010334915B2 (en) 2014-11-06
CN102933548B (zh) 2015-03-11
ZA201204496B (en) 2013-02-27
IL220586A (en) 2015-10-29
MX2012007323A (es) 2012-11-06
US20110152265A1 (en) 2011-06-23
WO2011076811A1 (en) 2011-06-30
US9051304B2 (en) 2015-06-09
CA2783704A1 (en) 2011-06-30
EP2516393A1 (en) 2012-10-31
AU2010334915A1 (en) 2012-06-21
NZ600342A (en) 2013-12-20
CN102933548A (zh) 2013-02-13
EP2516393B1 (en) 2014-10-29
AR079668A1 (es) 2012-02-08
JP5726207B2 (ja) 2015-05-27
RU2012131276A (ru) 2014-01-27
HK1176066A1 (en) 2013-07-19
SG181915A1 (en) 2012-07-30
RU2567392C2 (ru) 2015-11-10
TW201138771A (en) 2011-11-16
US20150252017A1 (en) 2015-09-10
KR20120102132A (ko) 2012-09-17

Similar Documents

Publication Publication Date Title
BR112012015659A2 (pt) compostos de carboxamida e seu uso como inibidores de calpaína
BR112015025413A2 (pt) inibidores de proteína cinase
MD4582C1 (ro) Derivaţi ai 1-fenil-1H-benzimidazolului ca inhibitori ai protein kinazei
CY1121357T1 (el) Νεος ανοσοτροποποιητης και αντιφλεγμονωδεις ενωσεις
BR112014013661A8 (pt) derivados de nucleosídeos 2’,4’-difluoro-2’-metil substituídos como inibidores de replicação de hcv-rna
BR112015025260A2 (pt) compostos heterocíclicos fundidos como inibidores da proteína quinase
CR20140519A (es) Derivados de benzamida para la inhibición de la actividad de abl 1, abl 2 y bcr-abl 1
EA201590453A1 (ru) Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b
BR112014029139A8 (pt) compostos inibidores da atividade de catecol o-metiltransferase
NI201200192A (es) Derivados de imidazopiridina, su procedimiento de preparación y su aplicación en terapéutica.
BR112012013322A2 (pt) derivados de amino oxazina
BR112014005226A2 (pt) derivados de benzonitrila como inibidores de cinase
ATE542813T1 (de) 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
EA201000947A1 (ru) Производные тиазола, применимые в качестве ингибиторов киназы pi3
CY1121248T1 (el) Πολυμορφικες μορφες κι αλατα 6-(1h-ινδολ-4-υλ)-4-(5-{[4-(1-μεθυλαιθυλο)-1-πιπεραζινυλ]μεθυλο}-1,3-οξαζολ-2-υλ)-1η-ινδαζολιου ως αναστολεις ρi3κ για χρηση στη θεραπεια π.χ. αναπνευστικων διαταραχων
EA201000113A1 (ru) Пиразольные соединения
ATE552255T1 (de) 4-aminoindazole
BR112015005817A2 (pt) compostos de bis(fluoroalquil)-1,4-benzodiazepinona como inibidores de notch
CR11433A (es) Inhibidores de quinasa c-fms
EA201190227A1 (ru) Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ
BR112012017382A2 (pt) compostos inibidores de viroses flaviviridae, uso dos mesmos e composição farmacêutica
BRPI0617548A2 (pt) Inibidores da quinase
BR112014002675A2 (pt) "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição"
BR112012010186A2 (pt) derivados de heteroarila contendo n como inibidores de quinase jak3.
EA201390163A1 (ru) Гетеробициклические производные в качетстве ингибиторов hcv

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)
B25B Requested transfer of rights rejected

Owner name: ABBOTT GMBH AND CO KG (DE) , ABBOTT LABORATORIES (